Effects of Omalizumab in Non-Atopic Asthma: Results from a Spanish Multicenter Registry

Journal of Asthma

Volumn 50, Issue 3, 2013, Pages 296-301

  De Llano, Luis Pérez ^a   Vennera, María Del Carmen ^b,c,d   Álvarez, Francisco J ^e   Medina, Juan F ^e   Borderías, Luis ^f   Pellicer, Concha ^g   González, Héctor ^h   Gullón, José A ^h   Martínez Moragón, Eva ⁱ   Sabadell, Carlos ^j   Zamarro, Soledad ^k   Picado, César ^b,c,d  

^a HOSPITAL XERAL CALDE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL SAN JORGE   (Spain)

^g HOSPITAL FRANCESC DE BORJA   (Spain)

^h HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

ⁱ HOSPITAL DE SAGUNTO   (Spain)

^j Hospital de Figueras   (Spain)

^k HOSPITAL RAFAEL MÉNDEZ   (Spain)

more..

Author keywords

Efficacy; IgE mediated diseases; Non allergic patients; Omalizumab; Uncontrolled severe asthma

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E; OMALIZUMAB;

ARTICLE; ASTHMA; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEMOGRAPHY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; NON ATOPIC ASTHMA;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SPAIN; STATISTICS, NONPARAMETRIC;

EID: 84874914555     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2012.757780     Document Type: Article

References (32)

1. European Network for Understanding Mechanisms of Severe Asthma (ENFUMOSA). The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J 2003; 22(3):470-7.
2. Wenzel SE, Busse WW. National heart, lung, and blood institute's severe asthma research program. Severe asthma: lessons from the severe asthma research program. J Allergy Clin Immunol 2007; 119(1):14-21.
3. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, Calhoun WJ, Castro M, Chung KF, Clark MP, Dweik RA, Fitzpatrick AM, Gaston B, Hew M, Hussain I, Jarjour NN, Israel E, Levy BD, Murphy JR, Peters SP, Teague WG, Meyers DA, Busse WW, Wenzel SE. National heart, lung, blood institute's severe asthma research program. Characterization of the severe asthma phenotype by the national heart, lung, and blood institute's severe asthma research program. J Allergy Clin Immunol 2007; 119(2):405-413.
4. Miller MK, Johnson C, Miller DP, Deniz Y, Bleecker ER, Wenzel SE. Severity assessment in asthma: An evolving concept. J Allergy Clin Immunol 2005; 116:990-S.
5. MooreWC, MeyersDA, Wenzel SE, TeagueWG, Li H, LiX, D'Agostino RJr, Castro M, Curran-Everett D, Fitzpatrick AM, Gaston B, Jarjour NN, Sorkness R, Calhoun WJ, Chung KF, Comhair SA, Dweik RA, Israel E, Peters SP, Busse WW, Erzurum SC, Bleecker ER. National heart, lung, and blood institute's severe asthma research program. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med 2010; 181(4):315-323.
6. Humbert M, BeasleyR, Ayres J, SlavinR, Hébert J, Bousquet J, BeehKM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60(3):309-316.
7. Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008; 102(1):71.
8. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham I. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009; 103(11):1633-1642.
9. Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009; 103(11):1725-1731.
10. Cazzola M, Camiciottoli G, BonaviaM, Gulotta C, Ravazzi A, Alessandrini A, Caiaffa MF, Berra A, Schino P, Di Napoli PL, Maselli R, Pelaia G, Bucchioni E, Paggiaro PL, Macchia L. Italian real-life experience of omalizumab. Respir Med 2010; 104(10):1410-1416.
11. VenneraMD, PérezDe Llano L, Bardagí S, Ausin P, Sanjuas C, Gonzǎlez H, Gullón JA, Martínez-Moragón E, Carretero JA, Vera E, Medina JF, Alvarez FJ, Entrenas LM, Padilla A, Irigaray R, Picado C; on behalf of the Spanish Registry. Omalizumab Therapy in Severe Asthma: Experience from the Spanish Registry-Some New Approaches. J Asthma 2012; 49(4):416-22.
12. GEMA. 2009. Guia Española para el manejo del asma. Editorial Luzan 5. Madrid. Available at: www.gemasma.com. Accessed March 20, 2012.
13. GINA. 2006. Global Initiative for Asthma. Global strategy for asthma management and prevention.NHLBI/WHOworkshop report updatedDecember 2011. Available at: http://www.ginasthma.com. AccessedMarch 20, 2012.
14. VegaJM, BadiaX, BadiolaC, López-ViñaA, OlaguíbelJM, PicadoC, Sastre J, Dal-Ré R; Covalair Investigator Group. Validation of the Spanish version of theAsthma Control Test (ACT). J Asthma 2007; 44(10):867-72.
15. Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Respir Med. 2009; 103(8):1098-113.
16. Bousquet J, Siergiejko Z, Swiebocka E, Humbert M, Rabe KF, Smith N, Leo J, Peckitt C, Maykut R, Peachey G. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy. 2011; 66(5): 671-8.
17. Van den Berge M, Pauw RG, deMonchy JG, vanMinnen CA, Postma DS, Kerstjens HA. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest 2011; 139(1):190-193.
18. Menzella F, Piro R, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L. Long-term benefits of omalizumab in a patient with severe non-allergic asthma. Allergy Asthma Clin Immunol 2011; 7(1):9.
19. Sugino Y, SandaR, TakagiY, KatoM, OhtaA, Okumura J, Nagai H.Acase of severe asthma responsive toomalizumabtreatmentdespite a lowserumIgE level and lack of sensitized allergens. Arerugi 2010; 59(11):1572-9.
20. Humbert M, Durham SR, Ying S, Kimmit P, Barkans J, Assoufi B, Pfister R, Menz G, Robinson DS, Kay AB, Corrigan CJ. IL-4 and IL-5mRNA and protein in bronchial biopsies from patients with atopic and non-atopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996; 154:1497-04.15.
21. Humbert M, Durham SR, Kimmit P, Powell N, Assoufi B, Pfister R, Menz G, Kay AB, Corrigan CJ. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and non-atopic subjects with asthma. J Allergy Clin Immunol 1997; 99:657-65.
22. Ying S, Humbert M, Meng Q, Pfister R, Menz G, Gould HJ, Kay AB, Durham SR. Local expression of e germline gene transcripts and RNA for the e heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. J Allergy Clin Immunol 2001; 107:686-92.
23. Humbert M, Grant JA, Taborda-Barata L, Durham SR, Pfister R, Menz G, Barkans J, Ying S, Kay AB. High-affinity IgE receptor (FceRI)- bearing cells in bronchial biopsies from atopic and non-atopic asthma. Am J Respir Crit Care Med 1996; 153:1931-7.
24. Takhar P, Corrigan CJ, Smurthwaite L, O'Connor BJ, Durham SR, Lee TH, Gould HJ. Class switch recombination to IgE in the bronchial mucosa of atopic and non-atopic patients with asthma. J Allergy Clin Immunol 2007; 119(1):213-218.
25. Bhat KD, Calhoun WJ. Omalizumab in asthma: is the therapeutic window too small?. Chest 2011; 139(1):8-10.
26. Pearlman AN, Chandra RK, Chang D, Conley DB, Tripathi-Peters A, Grammer LC, Schleimer RT, Kern RC. Relationships between severity of chronic rhinosinusitis and nasal polyposis, asthma, and atopy. Am J Rhinol Allergy 2009; 23:145-148.
27. Bachert C, Claeys SE, Tomassen P, van Zele T, Zhang N. Rhinosinusitis and asthma: a link for asthma severity. Curr Allergy Asthma Rep 2010; 10:194-201.
28. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L. TENOR Study Group. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116:970-975.
29. Wechsler ME, Kelley JM, Boyd IO, Dutile S, Marigowda G, Kirsch I, Israel E, Kaptchuk TJ. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med. 2011; 365(2):119-26.
30. Bardelas J, Figliomeni M, Kianifard F, Meng X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma 2012; 49(2):144-52.
31. Barbee R, Lebowitz M, Thompson H, Burrows B. Immediate skin-test reactivity in a general population sample. Ann Intern Med 1976; 84:129-133.
32. Tschopp JM, Sistek D, Schindler C, Leuenberger P, Perruchoud AP, Wuthrich B, Brutsche M, Zellweger JP, Karrer W, Brandli O. Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the Sapaldia Study. Swiss study on air pollution and lung diseases in adults. Allergy 1998; 53:608-613.